Pliant Therapeutics(PLRX)
$0.78-0.01 (-1.02%)
PLRX
Pliant Therapeutics financials statements
$0.78
At close:-0.01 (-1.02%)
Want to see PLRX full AI Analyst Report?
Pliant Therapeutics (PLRX) Ratios
520 Followers
Pliant Therapeutics Ratios
PLRX's free cash flow for Q2 2026 was $-12.80M. For the 2026 fiscal year, PLRX's free cash flow was increased by $0.00 and operating cash flow was $-12.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 |
| Quick Ratio | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 |
| Cash Ratio | 2.78 | 2.14 | 2.22 | 1.41 | 3.07 |
| Solvency Ratio | -3.35 | -2.24 | -4.13 | -3.21 | -4.32 |
| Operating Cash Flow Ratio | -7.84 | -4.68 | -4.08 | -3.96 | -4.48 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 152.43M | $ 269.40M | $ 466.92M | $ 303.04M | $ 187.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.15 | 0.02 | 0.05 | 0.03 |
| Debt-to-Equity Ratio | 0.16 | 0.20 | 0.02 | 0.05 | 0.04 |
| Debt-to-Capital Ratio | 0.14 | 0.17 | 0.02 | 0.05 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.09 | 0.02 | 0.03 | 0.00 |
| Financial Leverage Ratio | 1.24 | 1.31 | 1.08 | 1.12 | 1.11 |
| Debt Service Coverage Ratio | -56.70 | -67.84 | -124.88 | -150.25 | 0.00 |
| Interest Coverage Ratio | -58.65 | -75.52 | -145.34 | -160.81 | 0.00 |
| Debt to Market Cap | 0.00 | 0.04 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.52 | 1.04 | 0.22 | 0.40 | 0.20 |
| Net Debt to EBITDA | 0.11 | 0.05 | 0.33 | 0.15 | 0.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | -10130.95% | -1265.15% | -1284.51% |
| EBITDA Margin | 0.00% | 0.00% | -10014.43% | -1227.15% | -1264.24% |
| Operating Profit Margin | 0.00% | 0.00% | -11654.75% | -1313.37% | -1288.10% |
| Pretax Profit Margin | 0.00% | 0.00% | -10211.14% | -1273.32% | -1284.51% |
| Net Profit Margin | 0.00% | 0.00% | -10211.14% | -1273.32% | -1284.51% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -10211.14% | -1273.32% | -1284.51% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.51% | 92.09% | 87.61% | 96.95% | 99.72% |
| Return on Assets (ROA) | -66.31% | -52.98% | -31.50% | -35.17% | -43.97% |
| Return on Equity (ROE) | -82.42% | -69.16% | -34.07% | -39.36% | -48.86% |
| Return on Capital Employed (ROCE) | -71.85% | -62.78% | -38.08% | -38.93% | -47.72% |
| Return on Invested Capital (ROIC) | -71.36% | -62.69% | -37.97% | -38.64% | -47.29% |
| Return on Tangible Assets | -66.31% | -52.98% | -31.50% | -35.17% | -43.97% |
| Earnings Yield | -199.48% | -26.38% | -15.17% | -15.18% | -20.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.53 | 3.08 | 3.07 |
| Payables Turnover | 3.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.33 | 0.98 | 0.69 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Cash Conversion Cycle | -103.30 | 0.00 | 692.34 | 118.49 | 118.87 |
| Days of Sales Outstanding | 0.00 | 0.00 | 692.34 | 118.49 | 118.87 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 103.30 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 692.34 | 118.49 | 118.87 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.09 | -2.57 | -1.98 | -2.25 | -2.10 |
| Free Cash Flow Per Share | -2.10 | -2.63 | -2.00 | -2.29 | -2.16 |
| Dividend Paid and CapEx Coverage Ratio | -343.14 | -40.41 | -126.34 | -53.77 | -38.63 |
| Capital Expenditure Coverage Ratio | -343.14 | -40.41 | -126.34 | -53.77 | -38.63 |
| Operating Cash Flow Coverage Ratio | -4.41 | -2.58 | -10.23 | -5.98 | -10.49 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -73.65 | -9.77 | -9.96 |
| Free Cash Flow Yield | -171.92% | -19.99% | -11.03% | -11.87% | -15.99% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.50 | -3.80 | -6.59 | -6.59 | -4.98 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 673.04 | 83.86 | 63.91 |
| Price-to-Book (P/B) Ratio | 0.41 | 2.62 | 2.25 | 2.59 | 2.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.58 | -5.00 | -9.07 | -8.43 | -6.25 |
| Price-to-Operating Cash Flow Ratio | -0.58 | -5.13 | -9.14 | -8.58 | -6.41 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.14 | 1.02 | -0.78 | -0.04 |
| Enterprise Value Multiple | -0.40 | -3.83 | -6.39 | -6.68 | -4.59 |
| Enterprise Value | 58.53M | 786.30M | 1.01B | 794.30M | 439.46M |
| EV to EBITDA | -0.40 | -3.83 | -6.39 | -6.68 | -4.59 |
| EV to Sales | 0.00 | 0.00 | 640.22 | 82.01 | 58.04 |
| EV to Free Cash Flow | -0.45 | -4.93 | -8.62 | -8.24 | -5.68 |
| EV to Operating Cash Flow | -0.46 | -5.06 | -8.69 | -8.39 | -5.83 |
| Tangible Book Value Per Share | 2.95 | 5.02 | 8.07 | 7.46 | 5.55 |
| Shareholders’ Equity Per Share | 2.95 | 5.02 | 8.07 | 7.46 | 5.55 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.03 | 0.23 | 0.21 |
| Net Income Per Share | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.01 | 1.01 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 80.88 | 10.01 | 10.24 |
| SG&A to Revenue | 0.00 | 0.00 | 36.66 | 4.12 | 3.64 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 28.15 | 2.33 | 1.38 |
| Income Quality | 0.86 | 0.74 | 0.72 | 0.77 | 0.78 |
Currency in USD
